DOCSLIB.ORG

Commemorative Book Letter from Mary Woolley

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Commemorative Book Letter from Mary Woolley About Research!America Research!America is the nation’s largest 501(c) (3) public education and advocacy alliance working to make research to improve health a higher national priority. Founded in 1989, Research!America is supported by member institutions, organizations and businesses that together represent the voices of more than 100 million Americans. Our public opinion polls, advocacy programs and publications reach the public and decision makers to help advance medical, health and scienti c research. 1101 King Street, Suite 520 Alexandria, VA 22314-2960 703.739.2577 phone 703.739.2372 fax www.researchamerica.org 25th Anniversary Commemorative Book Letter from Mary Woolley In the late 1980s, visionary champions for medical research convened to address the widening gap between the extraordinary promise of research and the less-than-robust support it was then garnering from the public and its elected representatives. These leaders believed that allowing this gap to continue would be detrimental to Americans for years to come. They resolved to form a national alliance with a broad membership base and a singular focus on advocacy for research. Today, the Research!America alliance represents the voices of more than100 million Americans from academia, independent research institutes and hospitals, scientific societies, state and local organizations, voluntary health groups, and pharmaceutical, biotech and medical device manufacturing industries. In partnership with our mem- bers, we have successfully secured more funding for our nation’s federal health agencies; advocated for smarter policies that empower, rather than impede, private sector innovators; and most importantly, helped unleash scientific opportunity, leading to unprecedented medical progress. Our work is far from over. In the next 25 years we will neither lower our expectations nor shirk from the challenge of ensuring that our voices are heard when it comes to making research for health a much higher national priority. I thank the members of our alliance, current and emeritus Board members, our partners, BE WELL. and every champion of research for the work you have done and continue to do to realize the vision of our founders. With your ongoing support, I am confident we will NOT A WISH. A PROMISE. ensure that progress continues unabated and that research to improve health becomes the number one priority that Americans expect and deserve. For more than 150 years, a very special passion has driven the people of Merck. Our goal is to develop medicines, vaccines, consumer care and animal health innovations that will improve the lives of millions. Still, we know there is much more to be done. And we’re doing it, with a long-standing commitment to research and development. We’re just as committed to expanding access to healthcare and working with others who share our passion to create a healthier world. Together, we’ll meet that Mary Woolley challenge. Promise. President and CEO For more information about getting Merck medicines and vaccines for free, visit merckhelps.com or call 800-727-5400. Copyright © 2012 Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. All Rights Reserved. CORP-1060080-0000 11/12 181137_25_Anniv_Book.indd 1 1/29/14 10:16 AM When it comes to the next big idea, As a Founding Member of Research!America research holds the key. Duke University and Duke Medicine Salute Research!America's 25 Years of Innovative Advocacy The AMA stands united with Research!America in the work you do to help physicians care for patients. Advances in medical research don’t just happen. Vision, commitment, collaboration, a willingness to invest in the unknown—all are needed to unlock such mysteries as the human genome, drug therapies and stem cell research. At the American Medical Association we know robust research underpins our mission to improve the art and science of medicine and the betterment of public health. As the physician organization whose reach extends across the entire profession, we’re investing significant effort and resources toward achieving three ambitious goals: n Improving health outcomes for patients n Improving opportunities for physicians to provide high-quality care n Improving training for a new generation of medical students The AMA is working to significantly improve the health of the nation. Learn more. ama-assn.org/go/strategic-focus Research!America Leadership, 2013 – 2014 Board of Directors __________________________________________Officers Jay A. Gershen, DDS, PhD James L. Madara, MD __________________________________________Emeritus Directors President Chief Executive Officer and Executive Vice President Hon. John Edward Porter, Chair Northeast Ohio Medical University American Medical Association William G. Anlyan, MD Myron Genel, MD James E. Mulvihill, DMD Randolph Siegel Partner Irma E. Goertzen William D. Novelli Samuel C. Silverstein, MD Hogan Lovells US LLP William N. Hait, MD, PhD Mark McClellan, MD, PhD Dennis A. Ausiello, MD Global Head Director, Engelberg Center for Health Care Reform Kenneth I. Berns, MD, PhD M.R.C. Greenwood, PhD William A. Peck, MD Hon. Louis Stokes Hon. Michael N. Castle, Vice Chair Janssen Research & Development, LLC Brookings Institution William R. Brinkley, PhD Elmer E. Huerta, MD, MPH Edward E. Penhoet, PhD Hon. Louis W. Sullivan, MD Partner DLA Piper, LLP Mary J. C. Hendrix, PhD Hon. Kweisi Mfume Roger J. Bulger, MD Robert A. Ingram William L. Roper, MD, MPH Hon. Billy Tauzin President and Scientific Director G. Steven Burrill Caroline A. Kovac, PhD Leon E. Rosenberg, MD Reed V. Tuckson, MD Mary Woolley, President Ann & Robert H. Lurie Children’s Hospital of Chicago Elizabeth Nabel, MD Gail H. Cassell, PhD Philip R. Lee, MD Isadore Rosenfeld, MD Christopher A. Viehbacher Chief Executive Officer Research Center President Research!America Brigham and Women’s Hospital Wendy Chaite, Esq. Ellen Levine Raymond R. Sackler, MD Alan G. Walton, DSc, PhD Martha N. Hill, PhD, RN Jordan J. Cohen, MD Constance E. Lieber Charles A. Sanders, MD M. Cass Wheeler Larry J. Shapiro, MD, Secretary Professor of Nursing, Medicine and Public Health Herbert Pardes, MD Executive Vice Chancellor for Medical Affairs and Dean The Johns Hopkins University School of Nursing Executive Vice Chair Sam Donaldson John P. Margaritis Mitchel Sayare, PhD John Whitehead NewYork-Presbyterian Hospital of the School of Medicine John P. Donnelly Jewell Jackson McCabe Carol R. Scheman Ruth Wooden Washington University in St. Louis Harry Johns President and CEO Sudip S. Parikh, PhD Robert Dresing Catherine E. McDermott M. Roy Schwarz, MD Judy Woodruff Vice President & General Manager, Lucinda Maine, PhD, RPh, Treasurer Alzheimer’s Association Eugene Garfield, PhD Donnica L. Moore, MD Susan C. Scrimshaw, PhD James B. Wyngaarden, MD Health & Analytics Executive Vice President & CEO Jackie Lovelace Johnson Battelle American Association of Colleges of Pharmacy Chair of the Board Lovelace Respiratory Research Institute Amy Comstock Rick, JD __________________________________________Board Members: Chief Executive Officer Evan Jones Parkinson’s Action Network Tenley E. Albright, MD Managing Member Director, Collaborative Initiatives jVen Capital John R. Seffrin, PhD For more highlights Massachusetts Institute of Technology Chief Executive Officer Elizabeth Baker Keffer American Cancer Society Georges C. Benjamin, MD Vice President McGladrey congratulates of Research!America’s Executive Director The Atlantic Laing Rogers Sisto American Public Health Association President Community Leader Research!America on Atlantic LIVE last 25 years, please visit Nancy Brown Jack T. Watters, MD Chief Executive Officer Hon. Patrick Kennedy Vice President for External Medical Affairs their 25th Anniversary. American Heart Association Co-Chair Pfizer, Inc. www.researchamerica.org/25years One Mind for Research Susan Dentzer Keith R. Yamamoto, PhD Senior Health Policy Adviser Debra R. Lappin, JD Executive Vice Dean, School of Medicine ® Robert Wood Johnson Foundation Principal Professor, Cellular and Molecular Pharmacology Power comes from being understood. FaegreBD Consulting University of California, San Francisco Victor J. Dzau, MD Experience the power. Elias Zerhouni, MD Chancellor for Health Affairs Alan I. Leshner, PhD Go to www.mcgladrey.com. President, Global Research & Development Duke University Chief Executive Officer Contact Janette Burke at 866.239.8790. Sanofi President and CEO American Association for the Advancement Duke University Health System of Science © 2014 McGladrey LLP. All Rights Reserved. Joseph Feczko, MD Research!America salutes Herbert Pardes, MD, our longest serving board member, for more than 20 years of leadership and commitment. Research!America Leadership Looking Back at 25 Years of Leadership The Honorable Mary Woolley Founding Board of Founding Member Johnson & Johnson __________________________________ Massachusetts General Hospital John Edward Porter __________________________________________Directors __________________________________________Organizations __________________________________ Massachusetts Institute of Technology (MIT) Mary Woolley is the president of Jack Whitehead (Deceased) AdvaMed (Advanced Medical Memorial Sloan-Kettering Cancer Center The Honorable John Edward Porter, Research!America. During her 23 years of Virginia Weldon Technology Association) Merck & Co., Inc. Ed Greissing, Jr. Albert Einstein College of Medicine Morehouse School of Medicine a stalwart advocate of health and leadership, Research!America
Load more

Recommended publications
  • NINR History Book
    NINR NATIONAL INSTITUTE OF NURSING RESEARCH PHILIP L. CANTELON, PhD NINR: Bringing Science To Life National Institute of Nursing Research (NINR) with Philip L. Cantelon National Institute of Nursing Research National Institutes of Health Publication date: September 2010 NIH Publication No. 10-7502 Library of Congress Control Number 2010929886 ISBN 978-0-9728874-8-9 Printed and bound in the United States of America TABLE OF CONTENTS Preface The National Institute of Nursing Research at NIH: Celebrating Twenty-five Years of Nursing Science .........................................v Acknowledgments ..................................................................................................ix Chapter One Origins of the National Institute of Nursing Research .................................1 Chapter Two Launching Nursing Science at NIH ..............................................................39 Chapter Three From Center to Institute: Nursing Research Comes of Age .....................65 Chapter Four From Nursing Research to Nursing Science ............................................. 113 Chapter Five Speaking the Language of Science ............................................................... 163 Epilogue The Transformation of Nursing Science ..................................................... 209 Appendices A. Oral History Interviews .......................................................................... 237 B. Photo Credits ........................................................................................... 239
    [Show full text]
  • May 30, 1989, NIH Record, Vol. XLI, No. 11
    May 30. 1989 Vol. XU No. 11 U.S. Departmenr of Health and H uman Services National Institutes of Health NIH's 'Legislative Father' Director Reflects on 7½ Years at NIH Bldg. 31 Renamed; ll)' Rich McManus Honors Claude Pepper Par/ one ofa two-part ,eries Under rainy skies char were brighcened Sometime chis sumrner, NIH direccor Dr. purchasing power. During his 7 'Ii-year rerm, considerably by the music of rhe Marine Band, ]tunes B. Wyngaarden will relinquish whar rhc institutes have realized a 35-40 percent Bldg. 31 was recently renamed in honor of many consider the most powerful post in gain in purchasing power. Rep. Claude Denson Pepper (D.-Fla.). The American medicine. He will leave behind a Other statistics salure his dedication to legislative sponsor of all bur one NIH legacy t hat is ac once easily computed and stabilizing and promoting rhc advance of insciruce, Pepper was hailed as NIH's hard ro fathom. biomedical research. Boch the number and "legislative father." Easy co grasp are rhe achievements chat d uration of investigator-initiated research proj­ Hospitalized in recent weeks for a stomach numbers can capture. Arriving as dircccor on ect grams are up, a robust conscrucrion ailment, Pepper, 88, was unahle to attend the Feb. I, I 982 (though nor formally inducted program is under way on campus, vigorous ceremony rededicaring rhe 28-year-old office until Apr. 30), he gave himself the goal of and talented staff occupy virtually all top building. Speaking in his place was Sen. doubling the NIH bL1dget during his term.
    [Show full text]
  • Duke Health Named Professor
    advancing innovation + discovery Duke Health Named Professorships DUKE HEALTH to establish endowed scientific opportunities professorships are gifts here and around the world. Endowed professorships that last forever. Once Great universities succeed are the highest academic inaugurated, they continue on the strength of the honor that the Duke in perpetuity, passing in partnerships they form University School of time from one exceptional with their supporters and Medicine or School of faculty member to the benefactors. Everyone who Nursing can bestow upon a next. Every endowed establishes an endowed faculty member. professorship is both a professorship at Duke These prestigious profound honor for the Health joins with us in positions honor our most faculty member who holds our mission to deliver accomplished physician- it and a meaningful legacy tomorrow’s health care and nurse-scientists and to the visionary benefactor today, accelerate research clinicians. They celebrate who establishes it. and its translation, and Duke University those who demonstrate That legacy is evident in the create education that A. Eugene Washington, extraordinary achievement pages that follow, as we is transforming. We are School of Medicine in advancing scholarship, MD, MSc profile our philanthropic deeply grateful for these Introduction Chancellor for Health Affairs, science, and human Dean Mary E. Klotman, MD 5 Duke University partners who have partners, who, as you health. And perhaps most President and CEO, generously invested in will read, have propelled importantly, they nurture Duke University Health System endowed professorships our professors and our Nobel Prize Recipients 6 innovation, discovery, at Duke Health. They institution to even greater and the expansion of the have demonstrated heights of excellence and Donors & Professors 8 boundaries of knowledge.
    [Show full text]
  • Interview with Dr. James Wyngaarden (JW) Jennifer Midura (JM), Center for Public Genomics, Institute for Genome Sciences & Policy, Duke University December 8, 2006
    Interview with Dr. James Wyngaarden (JW) Jennifer Midura (JM), Center for Public Genomics, Institute for Genome Sciences & Policy, Duke University December 8, 2006 JM: The information I am about to give you and your response will now be recorded. My name is Jennifer Midura and I am a student at Duke University. I am in a course on the history of genomics that includes oral history. One goal is to produce a written transcript of interviews with important figures in genomics. Some of the interviews may be archived or made public through a website. I selected you as the person I would like to interview. The interview should last about 45 minutes. Your participation in this interview is strictly voluntary, and you may withdraw at any time. You do not have to answer every question asked. The information that you provide will be “on the record” and may be attributed to you. This interview is being recorded and I will take written notes during the interview. The interviews that are posted publicly will be archived as a history resource. If you prefer that the interview be used only for the course and not made public, please indicate this. One risk of this study is that you may disclose information that later could be requested for legal proceedings. Or you may say something that embarrasses you or offends someone else when they read it on a public website. The benefit of participating in this study is ensuring that your side of the story is properly portrayed in the history of genomics.
    [Show full text]
  • April 27, 1982, NIH Record, Vol. XXXIV, No. 9
    The NIH Record U.S. Department April 27 National of Health 1982 Institutes and Vol. XXXIV of Human Services No. 9 Health Dr. Martin Rosenberg NIH-Produced Film on Genital Herpes Wins Flemming Award Generates Considerable Public Interest Dr. Martin Rosenberg, chief of the cellu­ lar regulation section, NCI Laboratory of Recognizing the critical need for public Biochemistry, received the 33rd annual Ar­ education about genital herpes, the Office thur S. Flemming Award on Apr. 23 in of Research Reporting and Public Re­ Washington, D.C. sponse, National Institute of Allergy and The award was presented by Dr. Flem­ Infectious Diseases, and the NIH Audiovis­ ming, former DHEW Secretary (1958-1961), ual Branch have produced Jennifer: A Re­ and by Dr. Thomas E. Malone, Acting NIH vealing Story of Genital Herpes. This 28- Director. minute film shares the experience of a young woman striving to cope with her own case of genital herpes. Segments of this film have been tele­ vised on national network shows and also on local TV news and public service pro­ grams. Jennifer has been made available to physicians, health facilities, schools and In the film, Jennifer chats with Dr. Straus, civic groups on short-term loans. The re­ whose research group has successfully used sponse to initial promotional efforts has acyclovir to prevent recurrence of herpes virus been overwhelming. To date, more than infection. 500 loan requests from schools had to be edge and understanding of the signs and booked for the fall semester. symptoms of this disease, many people Infection with the virus causing genital with herpes unintentionally transmit it to herpes is on the upswing, reaching epi­ others.
    [Show full text]
  • Human Genome Project
    MARCH 2002 Managing “Big Science”: A Case Study of the Human Genome Project W. Henry Lambright Professor of Political Science and Public Administration and Director, Center for Environmental Policy and Administration The Maxwell School Syracuse University The PricewaterhouseCoopers Endowment for New Ways to Manage Series Ways New The Business of Government NEW WAYS TO MANAGE SERIES Managing “Big Science”: A Case Study of the Human Genome Project W. Henry Lambright Professor of Political Science and Public Administration and Director, Center for Environmental Policy and Administration The Maxwell School Syracuse University March 2002 1 TABLE OF CONTENTS Foreword..............................................................................................3 Executive Summary ..............................................................................4 The Human Genome Project Today......................................................6 The Human Genome Project: A Management Case History ..............10 Conceptualization, 1980–86 ..........................................................11 Adoption, 1986–90 ........................................................................13 Initial Implementation, 1990–93 ....................................................15 Maintaining Momentum and Growing, 1993–98 ..........................17 Reorientation, 1998–2001..............................................................20 Conclusions........................................................................................27 Goals ............................................................................................27
    [Show full text]
  • History of the Human Genome Project (HGP) and Subsequent Attempts to Integrate Scans of People’S Genomes Into Healthcare in Britain and the USA
    History of the Human Genome June 2010 This briefing is based on a timeline of key events in the history of the Human Genome Project (HGP) and subsequent attempts to integrate scans of people’s genomes into healthcare in Britain and the USA. The history shows that: Claims that human genome sequencing will be useful to predict who develops common diseases are false and originate from spurious findings published by tobacco-funded scientists. Nobel Prizewinner Sydney Brenner had secret meetings with British American Tobacco (BAT) in 1988 and 1990, in an attempt to secure funding for the Human Genome Project, and the Medical Research Council (MRC) jointly funded much of the spurious research. Leading scientists at the US National Institutes of Health (NIH) also endorsed the false findings in journals and the press. Other scientists who received tobacco industry research funding (for unrelated projects) included Nobel Prizewinner Harold Varmus – recently reappointed by President Obama to run the US National Cancer Institute – and Kari Stefansson, the President of pioneering gene test company DeCode Genetics. The food and pharmaceutical industries have also promoted false claims that human genome sequencing will predict big killer diseases, in an effort to expand the market for healthcare products to large numbers of healthy people and to confuse people about the role of unhealthy processed foods in hypertension, type 2 diabetes and obesity. False claims about health benefits from sequencing the genomes of whole populations led to the £12 billion decision by Tony Blair to centralise electronic medical records in the NHS. Billions in taxpayers’ money has been wasted in both Britain and the USA, and medical privacy has been jeopardised, in an attempt to create the vast databases of electronic medical records linked to DNA that will supposedly allow scientists to ‘predict and prevent’ disease.
    [Show full text]
  • Minutes of the National Advisory Council for Nursing Research
    Department of Health and Human Services National Institutes of Health National Institute of Nursing Research Minutes of the National Advisory Council for Nursing Research September 17–18, 2019 The 99thmeeting of the National Advisory Council for Nursing Research (NACNR) was convened on Tuesday, September 17, 2019, at 12:00 p.m. in Conference Room D, Building 45, Natcher, National Institutes of Health (NIH), Bethesda, Maryland. The first day of the meeting was an open session that started at 12:00 p.m. and adjourned that same day at 4:30 p.m. The closed session of the meeting, which included consideration of grant applications, was convened on Wednesday, September 18, 2019, at 9:00 a.m. and continued until adjournment at 12:15 p.m. Dr. Ann Cashion, Acting Chair, NACNR, presided over both sessions of the meeting. OPEN SESSION I. CALL TO ORDER, OPENING REMARKS, COUNCIL PROCEDURES, AND RELATED MATTERS—Dr. Ann Cashion, Acting Director, National Institute of Nursing Research (NINR) Dr. Cashion called the 99th meeting of the NACNR to order and welcomed all Council members, visitors, and staff. She introduced new Council members Drs. Peter Lewin and Eun-Ok Im and noted the absence of Council member Dr. Jeffrey Kelly. Conflict of Interest and Confidentiality Statement Dr. Nara Gavini, Acting Executive Secretary, NACNR, and Chief, Office of Extramural Programs, NINR, noted that the meeting was being webcast. He reminded attendees that NIH is a smoke-free campus. Dr. Gavini asked Council members to update their addresses on the meeting roster circulated during the meeting. Dr. Gavini referred to the conflict of interest and confidentiality statements provided in the Council materials and indicated that specific instructions would be provided at the beginning of the closed session on Wednesday.
    [Show full text]
  • March-April 2009 Capsules from Keystone Living History
    March-April 2009 WWW.IAVIREPORT.ORG | VOLUME 13, NUMBER 2 Capsules from Keystone FIRST IN A SERIES Living History Anthony Fauci on The Quest for a Vaccine “ We are living through one the most devastating pandemics ever to confront human civilization ” EDITor’s LETTER I am excited to introduce the inaugural installment of a new series, which we are calling “A Living History of AIDS Vaccine Research.” Its purpose is to provide perspective on historical moments in the quest for a vaccine, as well as insight into what lies ahead, as told by some of the leading researchers and policymakers in the field. We could not think of a better person to launch this series than Anthony Fauci, who has served as director of the National Institute of Allergy and Infectious Diseases (NIAID) for the past 25 years. Fauci has been immersed in the AIDS pandemic ever since the first cases were described 28 years ago. He was involved in the development of the first antiretrovirals to treat HIV infection and has played a pivotal role in AIDS vaccine research and development—from his early decision not to fund the first Phase III trial of an AIDS vaccine candidate to establishing the Vaccine Research Center at NIAID. iHe’s been one of the most vocal advocates and ardent supporters of the need for an AIDS vaccine and oversees a budget of US$460 million dedicated to AIDS vaccine research and development, 30% of NIAID’s overall HIV/AIDS budget. Whether Fauci is behind the podium at a conference or meeting with activists, he always eloquently captures both the current status of research and the human toll and devastation wrought by AIDS.
    [Show full text]
  • Physician-Scientist Workforce Working Group Report.Pdf
    National Institutes of Health Physician-Scientist Workforce Working Group Report June 2014 In a word, I consider hospitals only as the entrance to scientific medicine; they are the first field of observation which a physician enters; but the true sanctuary of medical science is a laboratory; only there can he seek explanations of life in the normal and pathological states by means of experimental analysis.1 Claude Bernard, 1865 1 Bernard, Claude, An Introduction to the Study of Experimental Medicine (Dover edition 1957; originally published in 1865; first English translation by Henry Copley Greene, published by Macmillan & Co., Ltd., 1927 i The Physician-Scientist Workforce Working Group David Ginsburg, MD, Co-Chair Rena N. D’Souza, DDS, PhD James V. Neel Distinguished University Professor and Dean, School of Dentistry Professor University of Utah Departments of Internal Medicine, Human Salt Lake City, UT Genetics, and Pediatrics and Communicable Diseases James G. Fox, DVM Howard Hughes Medical Institute Professor and Director of the Division of Comparative University of Michigan Medical School Medicine Ann Arbor, MI Professor, Department of Biological Engineering Massachusetts Institute of Technology Cambridge, MA Sherry Mills, MD, MPH, Co-Chair Director, Office of Extramural Programs Helen H. Hobbs, MD National Institutes of Health Investigator, Howard Hughes Medical Institute Bethesda, MD Professor of Internal Medicine and Molecular Genetics University of Texas Southwestern Medical Center Susan Shurin, MD, Co-Chair Dallas, TX Deputy Director, National Institute of Heart, Lung and Blood Ann R. Knebel, RN, PhD, FAAN National Institutes of Health Deputy Director Bethesda, MD National Institute of Nursing Research National Institutes of Health Nancy Andrews, MD, PhD Bethesda, MD Dean, Duke University School of Medicine Vice Chancellor for Academic Affairs Elaine Larson, RN, PhD, FAAN, CIC Nanaline H.
    [Show full text]
  • Gisler Et Al the Human Genome Project 20100315
    Exuberant innovation: The Human Genome Project Monika Gisler1, Didier Sornette2,3 and Ryan Woodard2 1ETH Zurich, D-ERDW, NO, CH-8092 Zürich, +41 78 919 5058 [email protected] (corresponding author) 2ETH Zurich, D-MTEC, Chair of Entrepreneurial Risks, Kreuzplatz 5, CH-8032 Zurich [email protected]; [email protected] 3Swiss Finance Institute, University of Geneva, 40 blvd. du Pont d’Arve, CH-1211 Geneva 4 “And all this back and forthing over who did what and what strategy was used and which money was public and which was private is probably going to sink below the radar screen.” (Francis Collins)1 “The prevailing view is that the genome is going to revolutionize biology, but in some way, it’s overhyped. In the end, the real insights are coming from individuals studying one gene at a time in real depth.” (Gerald Rubin)2 Abstract We present a detailed synthesis of the development of the Human Genome Project (HGP) from 1986 to 2003 in order to test the “social bubble” hypothesis that strong social interactions between enthusiastic supporters of the HGP weaved a network of reinforcing feedbacks that led to a widespread endorsement and extraordinary commitment by those involved in the project, beyond what would be rationalized by a standard cost-benefit analysis in the presence of extraordinary uncertainties and risks. The vigorous competition and race between the initially public project and several private initiatives is argued to support the social bubble hypothesis. We also present quantitative analyses of the concomitant financial bubble concentrated on the biotech sector. Confirmation of this hypothesis is offered by the present consensus that it will take decades to exploit the fruits of the HGP, via a slow and arduous process aiming at disentangling the extraordinary complexity of the human complex body.
    [Show full text]
  • March 9, 2007, NIH Record, Vol. LIX, No. 5
    MARCH 9, 2007 The Second Best Thing About Payday VOL. LIX, NO. 5 ‘We Are Turning the Corner’ Reauthorization Signals Renewed Confidence in NIH, ABOVE · Dr. Frosty was seen outside Bldg. Zerhouni Says 12 following a recent snowfall. See p. 7. By Rich McManus hen President Bush signed into law the National Institutes of Health Reform features W Act of 2006 on Jan. 15—the agency’s third omnibus reauthorization in history 1 and first since 1993—it signaled renewed confidence in the NIH mission, its employ- Zerhouni Explains Impact of NIH ees and its leadership, said NIH director Dr. Elias Zerhouni. Reauthorization While he anticipates no short-term change in the way NIH operates day to day—af- 3 ter all, the Roadmap for Medical Research has been a prototype embodying the princi- Mahoney Lecture To Feature ples of reauthorization since 2003—Zerhouni sees nothing but benefits emerging from Morimoto a reauthorization process that has been evolving ever since the doubling of the NIH budget from 1998 to 2003 mandated a fresh look at how a bigger agency functions. 5 New Program Focuses on Genetic To Zerhouni, reauthorization “institutionalizes the concept that there are areas of Eye Diseases science where all of us have to come together on a regular basis and exchange concepts and ideas about fields of science that are either emerging, or need to be incubated, that 16 NIH-Discovery Channel Show need to be promoted, reinforced. Essentially, it’s a Common Fund for common shared Debuts purposes across all the institutes. “There will be some cultural shift in the way we will work in the future,” he contin- see reauthorization, page 8 departments Metabolic Clinical Research Unit Opens From Bench to With Ribbon-Cutting Ceremony Frontline Briefs 2 By Jenny Haliski Innovative Care Training 14 Keeps Kids Out Volunteers 15 On Jan.
    [Show full text]